Fosamprenavir: drug development for adherence.

Hester EK, Chandler HV, Sims KM.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1301-10. Epub 2006 Jun 6. Review.

PMID: 16757678 [PubMed - indexed for MEDLINE]

Related Articles

Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.

Chapman TM, Plosker GL, Perry CM.

Drugs. 2004;64(18):2101-24. Review.

PMID: 15341507 [PubMed - indexed for MEDLINE]

Related Articles

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.

MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W.

AIDS. 2004 Mar 5;18(4):651-5.

PMID: 15090770 [PubMed - indexed for MEDLINE]

Related Articles

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y, Stein DS.

AIDS. 2004 Apr 9;18(6):897-907.

PMID: 15060437 [PubMed - indexed for MEDLINE]

Related Articles

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.

Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A.

Antimicrob Agents Chemother. 2004 Mar;48(3):791-8.

PMID: 14982766 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.

PMID: 14707788 [PubMed - indexed for MEDLINE]

Related Articles

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ.

Antimicrob Agents Chemother. 2004 Jan;48(1):116-23.

PMID: 14693528 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

Chaudry NI, Eron JJ, Naderer OJ, Pereira AS, Wire MB, Fiscus SA, Kashuba AD.

Clin Infect Dis. 2002 Sep 15;35(6):760-2. Epub 2002 Aug 23.

PMID: 12203175 [PubMed - indexed for MEDLINE]

Related Articles

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.

Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT.

J Clin Pharmacol. 2002 Aug;42(8):887-98.

PMID: 12162471 [PubMed - indexed for MEDLINE]

Related Articles

[New HIV-1 protease inhibitors in development]

Yoshimura K, Maeda K.

Nippon Rinsho. 2002 Apr;60(4):780-3. Review. Japanese.

PMID: 11968788 [PubMed - indexed for MEDLINE]

Related Articles

From amprenavir to GW433908.

Gatell JM.

J HIV Ther. 2001 Nov;6(4):95-9. Review. No abstract available.

PMID: 11740410 [PubMed - indexed for MEDLINE]

Related Articles